|
[1] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for hepatitis C:A 2015 update[J]. J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.
|
|
[2] RAO H, WEI L, LOPEZ-TALAVERA JC, et al. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection[J]. J Gastroenterol Hepatol, 2014, 29 (3) :545-553.
|
|
[3] LEE MH, YANG HI, LU SN, et al. Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma[J].Int J Cancer, 2014, 135 (5) :1119-1126.
|
|
[4] BENNETT H, WASER N, JOHNSTON K, et al. A review of the burden of hepatitis C virus infecion in China, Japan, South Korea and Taiwan[J]. Hepatol Int, 2015, 9 (3) :378-390.
|
|
[5] WEI L, ZHANG MX, XU M, et al. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin[J]. J Gastroenterol Hepatol, 2016, 31 (11) :1860-1867.
|
|
[6] WEI L, WANG FS, ZHANG MX, et al. Daclatasvir plus asunaprevir in treatment-na6ve patients with hepatitis C virus genotype 1b infection[J]. World J Gastroenterol, 2018, 24 (12) :1361-1372.
|
|
[7] PAWLOTSKY JM. Therapeutic implications of hepatitis C virus resistance to antiviral drugs[J]. Therap Adv Gastroenterol, 2009, 2 (4) :205-219.
|
|
[8] LOK AS, GARDINER DF, HZODE C, et al. Randomized trial of daclatasvir and asunaprevir with or without Peg IFN/RBV for hepatitis C virus genotype 1 null responders[J]. J Hepatol, 2014, 60 (3) :490-499.
|
|
[9] SUZUKI Y, IKEDA K, SUZUKI F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options[J]. J Hepatol, 2013, 58 (4) :655-662.
|
|
[10] KUMADA H, SUZUKI F, SUZUKI Y, et al. Randomized comparison of daclatasvir+asunaprevir versus telaprevir+peginterferon/ribavirin in Japanese hepatitis C virus patients[J]. J Gastroenterol Hepatol, 2016, 31 (1) :14-22.
|
|
[11] KUMADA H, SUZUKI Y, IKEDA K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection[J]. Hepatology, 2014, 59 (6) :2083-2091.
|
|
[12] MANNS M, POL S, JACOBSON IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b:A multinational, phase 3, multicohort study[J]. Lancet, 2014, 384 (9954) :1597-1605.
|
|
[13] WANG HL, LU X, YANG X, et al. Effectiveness and safety of daclatasvir plus asunaprevir for hepatitis C virus genotype 1b:Systematic review and meta-analysis[J]. J Gastroenterol Hepatol, 2017, 32 (1) :45-52.
|
|
[14] MCPHEE F, WEI L, XIE Q, et al. High SVR with DCV+ASV in HCV GT-1b Chinese, Koreans&Taiwanese without baseline NS5A polymorphisms[R]. APASL, 2016, P-0102.
|
|
[15] BARTELS DJ, SULLIVAN JC, ZHANG EZ, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment[J]. J Virol, 2013, 87 (3) :1544-1553.
|
|
[16] PAWLOTSKY JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens[J]. Gastroenterology, 2016, 151 (1) :70-86.
|
|
[17] WU S, KANDA T, NAKAMOTO S, et al. Hepatitis C virus protease inhibitor-resistance mutations:Our experience and review[J].World J Gastroenterol, 2013, 19 (47) :8940-8948.
|
|
[18] European Association for Study of Liver. EASL Recommendations on treatment of hepatitis C 2015[J]. Hepatology, 2015, 63 (1) :199-236.
|
|
[19] TERRAULT NA, LOK ASF, Mc MAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B:AASLD2018 hepatitis B guidance[J]. Hepatology, 2018, 67 (4) :1560-1599.
|
|
[20] LIU CJ. Treatment of patients with dual hepatitis C virus and hepatitis B virus infection:Resolved and unresolved issues[J]. J Gastroenterol Hepatol, 2014, 29 (1) :26-30.
|
|
[21] GUTIRREZ GARCA ML, MANZANO ALONSO ML, FERRER ROSIQUE J, et al. Hepatitis B virus in patients with chronic hepatitis C treated with direct antiviral agents[J]. Rev Esp Enferm Dig, 2018.[Epub ahead of print]
|
|
[22] WANG C, JI D, CHEN J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents[J]. Clin Gastroenterol Hepatol, 2017, 15 (1) :132-136.
|
DownLoad: